225 related articles for article (PubMed ID: 30805884)
1. Naloxone Deserts in NJ Cities: Sociodemographic Factors Which May Impact Retail Pharmacy Naloxone Availability.
Lozo KW; Nelson LS; Ramdin C; Calello DP
J Med Toxicol; 2019 Apr; 15(2):108-111. PubMed ID: 30805884
[TBL] [Abstract][Full Text] [Related]
2. Identifying barriers to dispensing naloxone: A survey of community pharmacists in North Carolina.
Rudolph SE; Branham AR; Rhodes LA; Hayes HH; Moose JS; Marciniak MW
J Am Pharm Assoc (2003); 2018; 58(4S):S55-S58.e3. PubMed ID: 30006187
[TBL] [Abstract][Full Text] [Related]
3. Naloxone Availability in Retail Pharmacies and Neighborhood Inequities in Access.
Egan KL; Foster SE; Knudsen AN; Lee JGL
Am J Prev Med; 2020 May; 58(5):699-702. PubMed ID: 32005590
[TBL] [Abstract][Full Text] [Related]
4. Naloxone Availability and Pharmacy Staff Knowledge of Standing Order for Naloxone in Pennsylvania Pharmacies.
Graves RL; Andreyeva E; Perrone J; Shofer FS; Merchant RM; Meisel ZF
J Addict Med; 2019; 13(4):272-278. PubMed ID: 30585876
[TBL] [Abstract][Full Text] [Related]
5. State laws that authorize pharmacists to prescribe naloxone are associated with increased naloxone dispensing in retail pharmacies.
Xu J; Mukherjee S
Drug Alcohol Depend; 2021 Oct; 227():109012. PubMed ID: 34482035
[TBL] [Abstract][Full Text] [Related]
6. Attitudes and availability: A comparison of naloxone dispensing across chain and independent pharmacies in rural and urban areas in Alabama.
Sisson ML; McMahan KB; Chichester KR; Galbraith JW; Cropsey KL
Int J Drug Policy; 2019 Dec; 74():229-235. PubMed ID: 31698165
[TBL] [Abstract][Full Text] [Related]
7. Assessing pharmacists' readiness to dispense naloxone and counsel on responding to opioid overdoses.
Melaragni F; Levy C; Pedrazzi J; Andersen M
J Am Pharm Assoc (2003); 2019; 59(4):550-554.e2. PubMed ID: 31109812
[TBL] [Abstract][Full Text] [Related]
8. Availability and Cost of Naloxone Nasal Spray at Pharmacies in Philadelphia, Pennsylvania, 2017.
Guadamuz JS; Alexander GC; Chaudhri T; Trotzky-Sirr R; Qato DM
JAMA Netw Open; 2019 Jun; 2(6):e195388. PubMed ID: 31173125
[TBL] [Abstract][Full Text] [Related]
9. Point-of-sale Naloxone: Novel Community-based Research to Identify Naloxone Availability.
Olives T; Willhite LA; Lee SC; Evans DK; Jensen A; Regelman HT; McGillis ES
West J Emerg Med; 2020 Aug; 21(5):1188-1194. PubMed ID: 32970574
[TBL] [Abstract][Full Text] [Related]
10. Pharmacy naloxone codispensing: A mixed methods study of practices and perspectives under a statewide standing order program.
Pollini RA; Slocum S; Ozga JE; Joyce R; Xuan Z; Green TC; Walley AY
J Am Pharm Assoc (2003); 2022; 62(5):1546-1554. PubMed ID: 35450833
[TBL] [Abstract][Full Text] [Related]
11. Pharmacists and Naloxone: Barriers to Dispensing and Effectiveness of an Educational Outreach Program.
Hanson KA; Smart MH; Mandava MR; Carkovic E; Aslamy M; Lee TA; Pickard AS
J Am Pharm Assoc (2003); 2023; 63(2):608-613.e3. PubMed ID: 36631342
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of naloxone access, pricing, and barriers to dispensing in Tennessee retail community pharmacies.
Spivey CA; Wilder A; Chisholm-Burns MA; Stallworth S; Wheeler J
J Am Pharm Assoc (2003); 2020; 60(5):694-701.e1. PubMed ID: 32146134
[TBL] [Abstract][Full Text] [Related]
13. Availability of Naloxone in Pharmacies and Knowledge of Pharmacy Staff Regarding Dispensing Naloxone to Younger Adolescents.
Jimenez DE; Singer MR; Adesman A
J Adolesc Health; 2019 Nov; 65(5):698-701. PubMed ID: 31540779
[TBL] [Abstract][Full Text] [Related]
14. Public Health and Pharmacy Partnerships in Opioid Harm Reduction: Responding to Community Needs.
Medina S; Tomaszewski R; Chhen S; Hanson A; Mueller A; Palombi LC
Prog Community Health Partnersh; 2021; 15(1):37-46. PubMed ID: 33775959
[TBL] [Abstract][Full Text] [Related]
15. Pharmacists' readiness to provide naloxone in community pharmacies in West Virginia.
Thornton JD; Lyvers E; Scott VGG; Dwibedi N
J Am Pharm Assoc (2003); 2017; 57(2S):S12-S18.e4. PubMed ID: 28163027
[TBL] [Abstract][Full Text] [Related]
16. Nonprescription naloxone and syringe sales in the midst of opioid overdose and hepatitis C virus epidemics: Massachusetts, 2015.
Stopka TJ; Donahue A; Hutcheson M; Green TC
J Am Pharm Assoc (2003); 2017; 57(2S):S34-S44. PubMed ID: 28189540
[TBL] [Abstract][Full Text] [Related]
17. Differences in prescription opioid analgesic availability: comparing minority and white pharmacies across Michigan.
Green CR; Ndao-Brumblay SK; West B; Washington T
J Pain; 2005 Oct; 6(10):689-99. PubMed ID: 16202962
[TBL] [Abstract][Full Text] [Related]
18. Predicting pharmacy naloxone stocking and dispensing following a statewide standing order, Indiana 2016.
Meyerson BE; Agley JD; Davis A; Jayawardene W; Hoss A; Shannon DJ; Ryder PT; Ritchie K; Gassman R
Drug Alcohol Depend; 2018 Jul; 188():187-192. PubMed ID: 29778772
[TBL] [Abstract][Full Text] [Related]
19. Barriers to Buprenorphine Dispensing by Medicaid-Participating Community Retail Pharmacies.
Freeman PR; Hammerslag LR; Ahrens KA; Sharbaugh M; Gordon AJ; Austin AE; Donohue JM; Allen LD; Barnes AJ; Talbert JC
JAMA Health Forum; 2024 May; 5(5):e241077. PubMed ID: 38758569
[TBL] [Abstract][Full Text] [Related]
20. Pharmacists' and technicians' perceptions and attitudes toward dispensing buprenorphine/ naloxone to patients with opioid dependence.
Raisch DW; Fudala PJ; Saxon AJ; Walsh R; Casadonte P; Ling W; Johnson BA; Malkerneker U; Ordorica P; Williford WO; Sather MR
J Am Pharm Assoc (2003); 2005; 45(1):23-32. PubMed ID: 15730114
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
